Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-007 in pediatric classic galactosemia
NCT04902781Phase 3Completed
- Sponsor
- Applied Therapeutics, Inc.
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in classic galactosemia comparing AT-007 with Placebo (2 arms). Primary endpoints: Global Statistical Test at 18 months, Sensitivity Analysis of the Primary Endpoint (GST) with Cognition at 18 months and 1 more. Started Mar 2021; status: completed.
02
Drugs
govorestat
03
Conditions
classic galactosemia
Beyond the preview
Go deeper on NCT04902781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902781.